Alexion Pharmaceuticals Inc. (ALXN)

130.21
NASDAQ : Health Technology
Prev Close 134.21
Day Low/High 130.10 / 134.90
52 Wk Low/High 92.56 / 140.77
Avg Volume 1.71M
Exchange NASDAQ
Shares Outstanding 223.47M
Market Cap 29.99B
EPS 0.30
P/E Ratio 383.46
Div & Yield N.A. (N.A)

Latest News

Alexion Announces Publication Of Interim Data From Phase 3 Open-Label Extension Study Supporting Long-Term Efficacy And Safety Of SOLIRIS® (Eculizumab) In Adult Patients With Generalized Myasthenia Gravis In Muscle & Nerve

Alexion Announces Publication Of Interim Data From Phase 3 Open-Label Extension Study Supporting Long-Term Efficacy And Safety Of SOLIRIS® (Eculizumab) In Adult Patients With Generalized Myasthenia Gravis In Muscle & Nerve

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the publication of data from an interim analysis of the Phase 3 open-label extension study (ECU-MG-302) of REGAIN (ECU-MG-301) evaluating the long-term efficacy and safety of SOLIRIS®...

Alexion To Present At The Cowen 39th Annual Health Care Conference

Alexion To Present At The Cowen 39th Annual Health Care Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the Cowen 39 th Annual Health Care Conference in Boston, MA on Tuesday, March 12, 2019 at 11:20 a.

Alexion Employees Raise Hands To Raise Awareness And #RallyforRare On Rare Disease Day

Alexion Employees Raise Hands To Raise Awareness And #RallyforRare On Rare Disease Day

Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) is honored to support Rare Disease Day 2019 with the launch of #RallyforRare, a global social media campaign that aims to raise awareness of rare diseases.

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.

Alexion To Present At The 8th Annual SVB Leerink Global Healthcare Conference

Alexion To Present At The 8th Annual SVB Leerink Global Healthcare Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the 8 th Annual SVB Leerink Global Healthcare Conference in New York, NY on Wednesday, February 27, 2019 at 11:00 a.

Alexion Pharma and Carnival Among Stocks Billionaire Ray Dalio Added in Q4

Alexion Pharma and Carnival Among Stocks Billionaire Ray Dalio Added in Q4

One of the world's largest hedge fund added these 'strong buy' stocks last quarter.

Alexion Announces Creation Of New Roles On Executive Leadership Team

Alexion Announces Creation Of New Roles On Executive Leadership Team

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced the creation of new roles within its executive leadership team.

Amazon, Your Game Plan, and More: Cramer's 'Mad Money' Recap (Friday 2/8/19)

Amazon, Your Game Plan, and More: Cramer's 'Mad Money' Recap (Friday 2/8/19)

Jim Cramer takes a closer look at Jeff Bezos, Amazon and your game plan for the end of earnings season.

Home Depot, U.S. Concrete, Marathon Petroleum: 'Mad Money' Lightning Round

Home Depot, U.S. Concrete, Marathon Petroleum: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Home Depot, U.S. Concrete, Marathon Petroleum, Constellation Brands, Alexion Pharmaceuticals and more.

Alexion Reports Fourth Quarter And Full Year 2018 Results

Alexion Reports Fourth Quarter And Full Year 2018 Results

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the fourth quarter and full year of 2018.

Alexion To Highlight Rare Disease Portfolio At Investor Day

Alexion To Highlight Rare Disease Portfolio At Investor Day

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that the Company will host an Investor Day on Wednesday, March 20, from 8:00am to 12:30pm ET.

Alexion And Caelum Biosciences Announce Collaboration To Develop Targeted Therapy For Light Chain (AL) Amyloidosis

Alexion And Caelum Biosciences Announce Collaboration To Develop Targeted Therapy For Light Chain (AL) Amyloidosis

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Caelum Biosciences today announced a collaboration to develop CAEL-101 for light chain (AL) amyloidosis.

Alexion Announces Positive Top-Line Results From Phase 3 Study Of ULTOMIRIS™ (Ravulizumab-cwvz) In Complement Inhibitor-Naïve Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Alexion Announces Positive Top-Line Results From Phase 3 Study Of ULTOMIRIS™ (Ravulizumab-cwvz) In Complement Inhibitor-Naïve Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Phase 3 study of ULTOMIRIS™ (ravulizumab-cwvz), the company's long-acting C5 complement inhibitor, met its primary objective in complement inhibitor-naïve patients with atypical...

Two Small-Caps and One Mid-Cap Stock I Like So Far in 2019

Two Small-Caps and One Mid-Cap Stock I Like So Far in 2019

It has been a better year for the Russell 2000 and the small-caps it represents.

Alexion To Report Fourth Quarter And Full Year 2018 Results On Monday, February 4, 2019

Alexion To Report Fourth Quarter And Full Year 2018 Results On Monday, February 4, 2019

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2018 before the US financial markets open on February 4, 2019.

Alexion To Present At The 37th Annual J.P. Morgan Healthcare Conference

Alexion To Present At The 37th Annual J.P. Morgan Healthcare Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the 37 th Annual J.

New Year's Investing Resolutions

New Year's Investing Resolutions

The market's day-to-day extreme volatility tested even the most seasoned investors. Adhering to portfolio principles can help.

Alexion To Present At The Goldman Sachs 11th Annual Healthcare CEO Conference

Alexion To Present At The Goldman Sachs 11th Annual Healthcare CEO Conference

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the Goldman Sachs 11th Annual Healthcare CEO Conference in New York, NY on Thursday, January 3, 2019 at 8 a.

(Photo: Business Wire)

(Photo: Business Wire)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the U.

Comprehensive Positive Phase 3 Data For Alexion's ALXN1210 In Patients With Paroxysmal Nocturnal Hemoglobinuria Presented At American Society Of Hematology (ASH) Annual Meeting And Published In Blood

Comprehensive Positive Phase 3 Data For Alexion's ALXN1210 In Patients With Paroxysmal Nocturnal Hemoglobinuria Presented At American Society Of Hematology (ASH) Annual Meeting And Published In Blood

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the presentation of comprehensive positive Phase 3 data for ALXN1210, the company's investigational long-acting C5 complement inhibitor, at the American Society of Hematology (ASH) Annual...

Alexion To Present At The Evercore ISI Healthcare Conference

Alexion To Present At The Evercore ISI Healthcare Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at Evercore ISI's Healthcare Conference in Boston, MA on Tuesday, November 27, 2018 at 8:45 a.

Alexion To Present At Credit Suisse's 27th Annual Healthcare Conference

Alexion To Present At Credit Suisse's 27th Annual Healthcare Conference

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at Credit Suisse's 27 th Annual Healthcare Conference in Scottsdale, AZ on Tuesday, November 13, 2018 at 10:00 a.

Alexion Completes Acquisition Of Syntimmune

Alexion Completes Acquisition Of Syntimmune

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the previously announced acquisition of Syntimmune has been successfully completed.

Alexion Announces Upcoming Data Presentations At American Society Of Hematology Annual Meeting

Alexion Announces Upcoming Data Presentations At American Society Of Hematology Annual Meeting

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that nine abstracts from its complement research and development program have been accepted for presentation at the American Society of Hematology (ASH) Annual Meeting in San Diego, December 1 to...

Alexion Reports Third Quarter 2018 Results

Alexion Reports Third Quarter 2018 Results

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the third quarter of 2018.

Alexion And Dicerna Announce Collaboration To Discover And Develop RNAi Therapies For Complement-Mediated Diseases

Alexion And Dicerna Announce Collaboration To Discover And Develop RNAi Therapies For Complement-Mediated Diseases

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Dicerna Pharmaceuticals, Inc.

Alexion To Report Third Quarter 2018 Results On Wednesday, October 24, 2018

Alexion To Report Third Quarter 2018 Results On Wednesday, October 24, 2018

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the third quarter ended September 30, 2018 before the US financial markets open on October 24, 2018.

TheStreet Quant Rating: C (Hold)